Use of the probasin promoter ARR2PB to express bax in androgen receptor-positive prostate cancer cells

Francesca Andriani, Bicheng Nan, Jiang Yu, Xiaoying Li, Nancy L. Weigel, Michael J. McPhaul, Susan Kasper, Shunsuke Kagawa, Bingliang Fang, Robert J. Matusik, Larry Denner, Marco Marcelli

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Adenovirus-mediated overexpression of the apoptosis-inducing protein Bax can induce apoptosis in prostate cancer cell lines. Constitutive overexpression of Bax could result in unwanted apoptosis in every site of accidental Bax accumulation in vivo. Therefore, we developed an adenoviral construct (Av-ARR2PB-Bax) in which the probasin promoter, modified to contain two androgen response elements, drives Bax expression. This promoter would be expected to limit expression of Bax to cells expressing the androgen receptor. Methods: A variety of androgen receptor (AR)-positive and -negative cell lines of prostatic or nonprostatic origin were infected with Av-ARR2PB-Bax or a control virus, Av-ARR2PB-CAT, in which the same promoter drives expression of the chloramphenicol acetyl transferase-reporter gene. Bax expression and apoptosis in vitro were assessed by western blot analysis. Tumor size and apoptosis in vivo were assessed after four weekly injections of Av-ARR2PB-Bax or Av-ARR2PB-CAT into subcutaneous LNCaP xenografts growing in uncastrated male mice. All statistical tests were two-sided. Results: Bax was overexpressed in an androgen-dependent way in AR-positive cell lines of prostatic origin but not in AR-positive cells of nonprostatic origin or in AR-negative cell lines of either prostatic or nonprostatic origin. The androgen dihydrotestosterone activated apoptosis in LNCaP cells infected with Av-ARR2PB-Bax but not in those infected with Av-ARR2PB-CAT. Av-ARR2PB-Bax-injected LNCaP xenograft tumors decreased in tumor size from 34.1mm3 (95% confidence interval [CI] = 25.1 mm3 to 43.1 mm3) to 24.6 mm3 (95% CI = -2.5 mm3 to 51.7 mm3), but the difference was not statistically significant (P = .5). Tumors injected with Av-ARR2PB-CAT increased in size, from 28.9 mm3 (95% CI = 12.7 mm3 to 45.1 mm3) to 206 mm3 (95% CI = 122 mm3 to 290 mm3) (P = .002) and contained statistically significant more apoptotic cells (23.3% [95% CI = 21.1% to 25.6%] versus 9.5% [95% CI = 8.0% to 11.1]) (P<.001). Conclusions: Av-ARR2PB-Bax induces androgen-dependent therapeutic apoptosis in vitro and in vivo by activating apoptosis in AR-positive cells derived specifically from prostatic epithelium and does not affect nonprostatic cells.

Original languageEnglish (US)
Pages (from-to)1314-1324
Number of pages11
JournalJournal of the National Cancer Institute
Volume93
Issue number17
StatePublished - Sep 5 2001
Externally publishedYes

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Apoptosis
Confidence Intervals
Androgens
Cell Line
Heterografts
Neoplasms
Apoptosis Regulatory Proteins
Dihydrotestosterone
Response Elements
Chloramphenicol
Transferases
probasin
Reporter Genes
Adenoviridae
Epithelium
Western Blotting
Viruses
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Andriani, F., Nan, B., Yu, J., Li, X., Weigel, N. L., McPhaul, M. J., ... Marcelli, M. (2001). Use of the probasin promoter ARR2PB to express bax in androgen receptor-positive prostate cancer cells. Journal of the National Cancer Institute, 93(17), 1314-1324.

Use of the probasin promoter ARR2PB to express bax in androgen receptor-positive prostate cancer cells. / Andriani, Francesca; Nan, Bicheng; Yu, Jiang; Li, Xiaoying; Weigel, Nancy L.; McPhaul, Michael J.; Kasper, Susan; Kagawa, Shunsuke; Fang, Bingliang; Matusik, Robert J.; Denner, Larry; Marcelli, Marco.

In: Journal of the National Cancer Institute, Vol. 93, No. 17, 05.09.2001, p. 1314-1324.

Research output: Contribution to journalArticle

Andriani, F, Nan, B, Yu, J, Li, X, Weigel, NL, McPhaul, MJ, Kasper, S, Kagawa, S, Fang, B, Matusik, RJ, Denner, L & Marcelli, M 2001, 'Use of the probasin promoter ARR2PB to express bax in androgen receptor-positive prostate cancer cells', Journal of the National Cancer Institute, vol. 93, no. 17, pp. 1314-1324.
Andriani, Francesca ; Nan, Bicheng ; Yu, Jiang ; Li, Xiaoying ; Weigel, Nancy L. ; McPhaul, Michael J. ; Kasper, Susan ; Kagawa, Shunsuke ; Fang, Bingliang ; Matusik, Robert J. ; Denner, Larry ; Marcelli, Marco. / Use of the probasin promoter ARR2PB to express bax in androgen receptor-positive prostate cancer cells. In: Journal of the National Cancer Institute. 2001 ; Vol. 93, No. 17. pp. 1314-1324.
@article{052715a685d143a594edc3864de3e873,
title = "Use of the probasin promoter ARR2PB to express bax in androgen receptor-positive prostate cancer cells",
abstract = "Background: Adenovirus-mediated overexpression of the apoptosis-inducing protein Bax can induce apoptosis in prostate cancer cell lines. Constitutive overexpression of Bax could result in unwanted apoptosis in every site of accidental Bax accumulation in vivo. Therefore, we developed an adenoviral construct (Av-ARR2PB-Bax) in which the probasin promoter, modified to contain two androgen response elements, drives Bax expression. This promoter would be expected to limit expression of Bax to cells expressing the androgen receptor. Methods: A variety of androgen receptor (AR)-positive and -negative cell lines of prostatic or nonprostatic origin were infected with Av-ARR2PB-Bax or a control virus, Av-ARR2PB-CAT, in which the same promoter drives expression of the chloramphenicol acetyl transferase-reporter gene. Bax expression and apoptosis in vitro were assessed by western blot analysis. Tumor size and apoptosis in vivo were assessed after four weekly injections of Av-ARR2PB-Bax or Av-ARR2PB-CAT into subcutaneous LNCaP xenografts growing in uncastrated male mice. All statistical tests were two-sided. Results: Bax was overexpressed in an androgen-dependent way in AR-positive cell lines of prostatic origin but not in AR-positive cells of nonprostatic origin or in AR-negative cell lines of either prostatic or nonprostatic origin. The androgen dihydrotestosterone activated apoptosis in LNCaP cells infected with Av-ARR2PB-Bax but not in those infected with Av-ARR2PB-CAT. Av-ARR2PB-Bax-injected LNCaP xenograft tumors decreased in tumor size from 34.1mm3 (95{\%} confidence interval [CI] = 25.1 mm3 to 43.1 mm3) to 24.6 mm3 (95{\%} CI = -2.5 mm3 to 51.7 mm3), but the difference was not statistically significant (P = .5). Tumors injected with Av-ARR2PB-CAT increased in size, from 28.9 mm3 (95{\%} CI = 12.7 mm3 to 45.1 mm3) to 206 mm3 (95{\%} CI = 122 mm3 to 290 mm3) (P = .002) and contained statistically significant more apoptotic cells (23.3{\%} [95{\%} CI = 21.1{\%} to 25.6{\%}] versus 9.5{\%} [95{\%} CI = 8.0{\%} to 11.1]) (P<.001). Conclusions: Av-ARR2PB-Bax induces androgen-dependent therapeutic apoptosis in vitro and in vivo by activating apoptosis in AR-positive cells derived specifically from prostatic epithelium and does not affect nonprostatic cells.",
author = "Francesca Andriani and Bicheng Nan and Jiang Yu and Xiaoying Li and Weigel, {Nancy L.} and McPhaul, {Michael J.} and Susan Kasper and Shunsuke Kagawa and Bingliang Fang and Matusik, {Robert J.} and Larry Denner and Marco Marcelli",
year = "2001",
month = "9",
day = "5",
language = "English (US)",
volume = "93",
pages = "1314--1324",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "17",

}

TY - JOUR

T1 - Use of the probasin promoter ARR2PB to express bax in androgen receptor-positive prostate cancer cells

AU - Andriani, Francesca

AU - Nan, Bicheng

AU - Yu, Jiang

AU - Li, Xiaoying

AU - Weigel, Nancy L.

AU - McPhaul, Michael J.

AU - Kasper, Susan

AU - Kagawa, Shunsuke

AU - Fang, Bingliang

AU - Matusik, Robert J.

AU - Denner, Larry

AU - Marcelli, Marco

PY - 2001/9/5

Y1 - 2001/9/5

N2 - Background: Adenovirus-mediated overexpression of the apoptosis-inducing protein Bax can induce apoptosis in prostate cancer cell lines. Constitutive overexpression of Bax could result in unwanted apoptosis in every site of accidental Bax accumulation in vivo. Therefore, we developed an adenoviral construct (Av-ARR2PB-Bax) in which the probasin promoter, modified to contain two androgen response elements, drives Bax expression. This promoter would be expected to limit expression of Bax to cells expressing the androgen receptor. Methods: A variety of androgen receptor (AR)-positive and -negative cell lines of prostatic or nonprostatic origin were infected with Av-ARR2PB-Bax or a control virus, Av-ARR2PB-CAT, in which the same promoter drives expression of the chloramphenicol acetyl transferase-reporter gene. Bax expression and apoptosis in vitro were assessed by western blot analysis. Tumor size and apoptosis in vivo were assessed after four weekly injections of Av-ARR2PB-Bax or Av-ARR2PB-CAT into subcutaneous LNCaP xenografts growing in uncastrated male mice. All statistical tests were two-sided. Results: Bax was overexpressed in an androgen-dependent way in AR-positive cell lines of prostatic origin but not in AR-positive cells of nonprostatic origin or in AR-negative cell lines of either prostatic or nonprostatic origin. The androgen dihydrotestosterone activated apoptosis in LNCaP cells infected with Av-ARR2PB-Bax but not in those infected with Av-ARR2PB-CAT. Av-ARR2PB-Bax-injected LNCaP xenograft tumors decreased in tumor size from 34.1mm3 (95% confidence interval [CI] = 25.1 mm3 to 43.1 mm3) to 24.6 mm3 (95% CI = -2.5 mm3 to 51.7 mm3), but the difference was not statistically significant (P = .5). Tumors injected with Av-ARR2PB-CAT increased in size, from 28.9 mm3 (95% CI = 12.7 mm3 to 45.1 mm3) to 206 mm3 (95% CI = 122 mm3 to 290 mm3) (P = .002) and contained statistically significant more apoptotic cells (23.3% [95% CI = 21.1% to 25.6%] versus 9.5% [95% CI = 8.0% to 11.1]) (P<.001). Conclusions: Av-ARR2PB-Bax induces androgen-dependent therapeutic apoptosis in vitro and in vivo by activating apoptosis in AR-positive cells derived specifically from prostatic epithelium and does not affect nonprostatic cells.

AB - Background: Adenovirus-mediated overexpression of the apoptosis-inducing protein Bax can induce apoptosis in prostate cancer cell lines. Constitutive overexpression of Bax could result in unwanted apoptosis in every site of accidental Bax accumulation in vivo. Therefore, we developed an adenoviral construct (Av-ARR2PB-Bax) in which the probasin promoter, modified to contain two androgen response elements, drives Bax expression. This promoter would be expected to limit expression of Bax to cells expressing the androgen receptor. Methods: A variety of androgen receptor (AR)-positive and -negative cell lines of prostatic or nonprostatic origin were infected with Av-ARR2PB-Bax or a control virus, Av-ARR2PB-CAT, in which the same promoter drives expression of the chloramphenicol acetyl transferase-reporter gene. Bax expression and apoptosis in vitro were assessed by western blot analysis. Tumor size and apoptosis in vivo were assessed after four weekly injections of Av-ARR2PB-Bax or Av-ARR2PB-CAT into subcutaneous LNCaP xenografts growing in uncastrated male mice. All statistical tests were two-sided. Results: Bax was overexpressed in an androgen-dependent way in AR-positive cell lines of prostatic origin but not in AR-positive cells of nonprostatic origin or in AR-negative cell lines of either prostatic or nonprostatic origin. The androgen dihydrotestosterone activated apoptosis in LNCaP cells infected with Av-ARR2PB-Bax but not in those infected with Av-ARR2PB-CAT. Av-ARR2PB-Bax-injected LNCaP xenograft tumors decreased in tumor size from 34.1mm3 (95% confidence interval [CI] = 25.1 mm3 to 43.1 mm3) to 24.6 mm3 (95% CI = -2.5 mm3 to 51.7 mm3), but the difference was not statistically significant (P = .5). Tumors injected with Av-ARR2PB-CAT increased in size, from 28.9 mm3 (95% CI = 12.7 mm3 to 45.1 mm3) to 206 mm3 (95% CI = 122 mm3 to 290 mm3) (P = .002) and contained statistically significant more apoptotic cells (23.3% [95% CI = 21.1% to 25.6%] versus 9.5% [95% CI = 8.0% to 11.1]) (P<.001). Conclusions: Av-ARR2PB-Bax induces androgen-dependent therapeutic apoptosis in vitro and in vivo by activating apoptosis in AR-positive cells derived specifically from prostatic epithelium and does not affect nonprostatic cells.

UR - http://www.scopus.com/inward/record.url?scp=0035812239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035812239&partnerID=8YFLogxK

M3 - Article

VL - 93

SP - 1314

EP - 1324

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 17

ER -